Summary
Professor Deborah Ashby is Director of the School of Public Health at Imperial College London where she holds the Chair in Medical Statistics and Clinical Trials, and was Founding Co-Director of Imperial Clinical Trials Unit. She is a Chartered Statistician and her research interests are in clinical trials, risk-benefit decision making for medicines, and the utility of Bayesian approaches in these areas.
She is the immediate Past President of the Royal Statistical Society. She has sat on the UK Commission on Human Medicines and acted as adviser to the European Medicines Agency. She has recently chaired the Population Research Committee for Cancer Research UK and the National Institute for Health Research HTA Commissioning Board, and was Deputy Chair of the HTA Programme. Deborah was awarded the OBE for services to medicine in 2009, appointed an NIHR Senior Investigator in 2010, and elected to the Academy of Medical Sciences in 2012.
Selected Publications
Journal Articles
Hughes D, Waddingham E, Mt-Isa S, et al., 2016, Recommendations for benefit-risk assessment methodologies and visual representations., Pharmacoepidemiology and Drug Safety, Vol:25, ISSN:1053-8569, Pages:251-262
Hallgreen CE, Mt-Isa S, Lieftucht A, et al., 2015, Literature review of visual representation of the results of benefit-risk assessments of medicinal products, Pharmacoepidemiology and Drug Safety, Vol:25, ISSN:1099-1557, Pages:238-250
Alton EWFW, Armstrong DK, Ashby D, 2015, Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fi brosis: a randomised, double-blind, placebo-controlled, phase 2b trial (vol 3, pg 684, 2015), Lancet Respiratory Medicine, Vol:3, ISSN:2213-2600, Pages:E33-E33
Alton EWFW, Armstrong DK, Ashby D, 2015, Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial, The Lancet Respiratory Medicine, Vol:3, ISSN:2213-2600, Pages:684-691
Mt-Isa S, Hallgreen CE, Wang N, et al., 2014, Balancing benefit and risk of medicines: a systematic review and classification of available methodologies, Pharmacoepidemiology and Drug Safety, Vol:23, ISSN:1053-8569, Pages:667-678
Lamb SE, Gates S, Williams MA, et al., 2013, Emergency department treatments and physiotherapy for acute whiplash: a pragmatic, two-step, randomised controlled trial, The Lancet, Vol:381, ISSN:0140-6736, Pages:546-556
Priebe S, Yeeles K, Bremner S, et al., 2013, Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial., British Medical Journal, Vol:347, ISSN:0959-535X
Elliott P, Chambers JC, Zhang W, et al., 2009, Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease, JAMA - Journal of the American Medical Association, Vol:302, ISSN:0098-7484, Pages:37-48
Eldridge S, Ashby D, Bennett C, et al., 2008, Internal and external validity of cluster randomised trials: systematic review of recent trials, British Medical Journal, Vol:336, ISSN:1756-1833, Pages:876-880
Underwood M, Ashby D, Cross P, et al., 2008, Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study, British Medical Journal, Vol:336, ISSN:1756-1833, Pages:138-142
Ashby D, 2006, Bayesian statistics in medicine: A 25 year review, Statistics in Medicine, Vol:25, ISSN:0277-6715, Pages:3589-3631
Reports
Hughes D, Waddingham EAJ, Mt-Isa S, et al., 2013, Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines